

Mantle Cell Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others), By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others}), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Report | 2025-05-16 | 185 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Multi-User License \$5500.00
- Custom Research License \$8000.00

Report description:

Market Overview

The Global Mantle Cell Lymphoma Market was valued at USD 2.53 billion in 2024 and is projected to reach USD 3.97 billion by 2030, growing at a CAGR of 7.80% during the forecast period. Mantle cell lymphoma (MCL), a rare and aggressive subtype of non-Hodgkin lymphoma, is characterized by the abnormal proliferation of B lymphocytes within the lymphatic system. Although MCL accounts for a small proportion of overall lymphoma cases, its rapid progression and limited curative treatment options make it a significant clinical concern. Recent years have seen substantial advancements in the field, particularly with the emergence of targeted therapies and immunotherapies aimed at improving patient outcomes. Traditional methods, such as chemotherapy and stem cell transplantation, have shown restricted long-term success, prompting a shift towards more specific and less toxic treatments. Notable breakthroughs include the introduction of Bruton's tyrosine kinase (BTK) inhibitors and phosphoinositide 3-kinase (PI3K) inhibitors, which interfere with critical pathways that sustain MCL cell survival and proliferation. These innovations are reshaping therapeutic strategies and expanding the market potential for MCL treatments.

Key Market Drivers

Advancements in Targeted Therapies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Technological progress in targeted therapies is a major catalyst for growth in the global mantle cell lymphoma market. MCL, known for its resistance to conventional treatments, has seen a significant transformation with the development of targeted approaches like BTK inhibitors, including ibrutinib, which specifically disrupt the BTK signaling protein that promotes tumor cell survival. These therapies have shown marked improvements in progression-free survival and patient quality of life, thereby attracting growing attention from healthcare providers and industry stakeholders. Additionally, PI3K inhibitors offer an alternative for patients not responding to BTK therapies, further diversifying the treatment landscape. The advancement of combination regimens, integrating multiple targeted agents, also holds promise for enhancing therapeutic efficacy and minimizing resistance. These innovations, supported by biomarker research and genetic profiling, are enabling more personalized treatment protocols and reinforcing the expansion of the MCL market.

Key Market Challenges

Heterogeneity of Disease

The complexity and variability of mantle cell lymphoma present a critical challenge to its clinical management and market growth. MCL encompasses a wide spectrum of disease behaviors-from indolent to highly aggressive subtypes-making it difficult to standardize treatment approaches. The diversity in disease progression among patients necessitates personalized therapy plans, which increases the difficulty of creating one-size-fits-all treatment models. Furthermore, the genetic heterogeneity of MCL tumors complicates drug development, as different mutations and molecular subtypes respond variably to treatment. This also hampers clinical trial design, as many studies focus on specific patient segments, limiting the generalizability of results across the broader MCL population.

Key Market Trends

Rising Investments and Funding

Increased investment and funding are playing a pivotal role in propelling the growth of the mantle cell lymphoma market. With the emergence of promising therapies, the MCL segment has attracted substantial attention from pharmaceutical companies, venture capitalists, and institutional investors. This surge in financial backing is accelerating research and development efforts, facilitating the introduction of innovative therapies and expanding access to advanced treatment options. Alongside private investment, public grants and nonprofit initiatives are also bolstering academic research, patient support services, and advocacy efforts. These combined financial inputs are enhancing manufacturing capabilities, supporting awareness campaigns, and strengthening the overall ecosystem for MCL treatment and management.

Key Market Players

- Kite Pharma, Inc. (Gilead Sciences, Inc.)
- F. Hoffman La Roche Ltd
- Abbvie, Inc.
- Celgene Corporation
- Eli Lilly and Company
- Amgen, Inc.
- Takeda Pharmaceutical Co. Ltd
- AstraZeneca Plc
- Johnson and Johnson Services Inc.
- BeiGene GmbH

Report Scope:

In this report, the Global Mantle Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- Mantle Cell Lymphoma Market, By Diagnosis:
 - o Laboratory Exams
 - o Imaging Tests
 - o Bone Marrow Biopsy
 - o Others
- Mantle Cell Lymphoma Market, By Treatment:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Diagnosis
- o Therapy
- Mantle Cell Lymphoma Market, By End User:
 - o Hospitals & Clinics
 - o Ambulatory Care Centers
 - o Others
- Mantle Cell Lymphoma Market, By Region:
 - o North America
 - United States
 - Canada
 - Mexico
 - o Europe
 - France
 - United Kingdom
 - Italy
 - Germany
 - Spain
 - o Asia-Pacific
 - China
 - India
 - Japan
 - Australia
 - South Korea
 - o South America
 - Brazil
 - Argentina
 - Colombia
 - o Middle East & Africa
 - South Africa
 - Saudi Arabia
 - UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mantle Cell Lymphoma Market.

Available Customizations:

Global Mantle Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
4. Global Mantle Cell Lymphoma Market Outlook
 - 4.1. Market Size & Forecast
 - 4.1.1. By Value
 - 4.2. Market Share & Forecast
 - 4.2.1. By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others)
 - 4.2.2. By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others})
 - 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
 - 4.2.4. By Region
 - 4.2.5. By Company (2024)
 - 4.3. Market Map
 - 4.3.1. By Diagnosis
 - 4.3.2. By Treatment
 - 4.3.3. By End User
 - 4.3.4. By Region
5. Asia Pacific Mantle Cell Lymphoma Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Diagnosis
 - 5.2.2. By Treatment
 - 5.2.3. By End User
 - 5.2.4. By Country
 - 5.3. Asia Pacific: Country Analysis
 - 5.3.1. China Mantle Cell Lymphoma Market Outlook
 - 5.3.1.1. Market Size & Forecast
 - 5.3.1.1.1. By Value
 - 5.3.1.2. Market Share & Forecast
 - 5.3.1.2.1. By Diagnosis
 - 5.3.1.2.2. By Treatment
 - 5.3.1.2.3. By End User
 - 5.3.2. India Mantle Cell Lymphoma Market Outlook
 - 5.3.2.1. Market Size & Forecast
 - 5.3.2.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.2.2. Market Share & Forecast
 - 5.3.2.2.1. By Diagnosis
 - 5.3.2.2.2. By Treatment
 - 5.3.2.2.3. By End User
- 5.3.3. Australia Mantle Cell Lymphoma Market Outlook
 - 5.3.3.1. Market Size & Forecast
 - 5.3.3.1.1. By Value
 - 5.3.3.2. Market Share & Forecast
 - 5.3.3.2.1. By Diagnosis
 - 5.3.3.2.2. By Treatment
 - 5.3.3.2.3. By End User
- 5.3.4. Japan Mantle Cell Lymphoma Market Outlook
 - 5.3.4.1. Market Size & Forecast
 - 5.3.4.1.1. By Value
 - 5.3.4.2. Market Share & Forecast
 - 5.3.4.2.1. By Diagnosis
 - 5.3.4.2.2. By Treatment
 - 5.3.4.2.3. By End User
- 5.3.5. South Korea Mantle Cell Lymphoma Market Outlook
 - 5.3.5.1. Market Size & Forecast
 - 5.3.5.1.1. By Value
 - 5.3.5.2. Market Share & Forecast
 - 5.3.5.2.1. By Diagnosis
 - 5.3.5.2.2. By Treatment
 - 5.3.5.2.3. By End User
- 6. Europe Mantle Cell Lymphoma Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Diagnosis
 - 6.2.2. By Treatment
 - 6.2.3. By End User
 - 6.2.4. By Country
 - 6.3. Europe: Country Analysis
 - 6.3.1. France Mantle Cell Lymphoma Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Diagnosis
 - 6.3.1.2.2. By Treatment
 - 6.3.1.2.3. By End User
 - 6.3.2. Germany Mantle Cell Lymphoma Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Diagnosis
 - 6.3.2.2.2. By Treatment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.2.2.3. By End User
- 6.3.3. Spain Mantle Cell Lymphoma Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Diagnosis
- 6.3.3.2.2. By Treatment
- 6.3.3.2.3. By End User
- 6.3.4. Italy Mantle Cell Lymphoma Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.1.1. By Value
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Diagnosis
- 6.3.4.2.2. By Treatment
- 6.3.4.2.3. By End User
- 6.3.5. United Kingdom Mantle Cell Lymphoma Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.1.1. By Value
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Diagnosis
- 6.3.5.2.2. By Treatment
- 6.3.5.2.3. By End User
- 7. North America Mantle Cell Lymphoma Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Diagnosis
- 7.2.2. By Treatment
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. North America: Country Analysis
- 7.3.1. United States Mantle Cell Lymphoma Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Diagnosis
- 7.3.1.2.2. By Treatment
- 7.3.1.2.3. By End User
- 7.3.2. Mexico Mantle Cell Lymphoma Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Diagnosis
- 7.3.2.2.2. By Treatment
- 7.3.2.2.3. By End User
- 7.3.3. Canada Mantle Cell Lymphoma Market Outlook
- 7.3.3.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Diagnosis
 - 7.3.3.2.2. By Treatment
 - 7.3.3.2.3. By End User
- 8. South America Mantle Cell Lymphoma Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Diagnosis
 - 8.2.2. By Treatment
 - 8.2.3. By End User
 - 8.2.4. By Country
 - 8.3. South America: Country Analysis
 - 8.3.1. Brazil Mantle Cell Lymphoma Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Diagnosis
 - 8.3.1.2.2. By Treatment
 - 8.3.1.2.3. By End User
 - 8.3.2. Argentina Mantle Cell Lymphoma Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Diagnosis
 - 8.3.2.2.2. By Treatment
 - 8.3.2.2.3. By End User
 - 8.3.3. Colombia Mantle Cell Lymphoma Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Diagnosis
 - 8.3.3.2.2. By Treatment
 - 8.3.3.2.3. By End User
 - 9. Middle East and Africa Mantle Cell Lymphoma Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Diagnosis
 - 9.2.2. By Treatment
 - 9.2.3. By End User
 - 9.2.4. By Country
 - 9.3. MEA: Country Analysis
 - 9.3.1. South Africa Mantle Cell Lymphoma Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Diagnosis
 - 9.3.1.2.2. By Treatment
 - 9.3.1.2.3. By End User
- 9.3.2. Saudi Arabia Mantle Cell Lymphoma Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Diagnosis
 - 9.3.2.2.2. By Treatment
 - 9.3.2.2.3. By End User
- 9.3.3. UAE Mantle Cell Lymphoma Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Diagnosis
 - 9.3.3.2.2. By Treatment
 - 9.3.3.2.3. By End User
- 10. Market Dynamics
 - 10.1. Drivers
 - 10.2. Challenges
- 11. Market Trends & Developments
 - 11.1. Recent Developments
 - 11.2. Product Launches
 - 11.3. Mergers & Acquisitions
- 12. Global Mantle Cell Lymphoma Market: SWOT Analysis
- 13. Porter's Five Forces Analysis
 - 13.1. Competition in the Industry
 - 13.2. Potential of New Entrants
 - 13.3. Power of Suppliers
 - 13.4. Power of Customers
 - 13.5. Threat of Substitute Product
- 14. Competitive Landscape
 - 14.1. Kite Pharma, Inc. (Gilead Sciences, Inc.)
 - 14.1.1. Business Overview
 - 14.1.2. Company Snapshot
 - 14.1.3. Products & Services
 - 14.1.4. Financials (In case of listed)
 - 14.1.5. Recent Developments
 - 14.1.6. Key Personnel Details
 - 14.1.7. SWOT Analysis
 - 14.2. F. Hoffman La Roche Ltd
 - 14.3. Abbvie, Inc.
 - 14.4. Celgene Corporation
 - 14.5. Eli Lilly and Company
 - 14.6. Amgen, Inc.
 - 14.7. Takeda Pharmaceutical Co. Ltd

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.8. AstraZeneca Plc
- 14.9. Johnson and Johnson Services Inc.
- 14.10. BeiGene GmbH
- 15. Strategic Recommendations
- 16. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Mantle Cell Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others), By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Report | 2025-05-16 | 185 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Multi-User License	\$5500.00
	Custom Research License	\$8000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>